A case report of reversible left ventricular dysfunction due to azathioprine hypersensitivity syndrome.

Background: Hypersensitivity reaction is a rare side effect during immunosuppressive treatment with azathioprine (AZA). Some cases of cardiac involvement have already been reported but causality is notoriously difficult to prove.

Case Summary: We present the case of a 68-year-old man with two episodes of reversible left ventricular (LV) dysfunction.

[Heart failure with preserved left ventricular ejection fraction (HFpEF)].

Heart failure with preserved left ventricular ejection fraction (HFpEF) is a common and very important disease entity because of its association with frequent repeat hospitalization and high mortality. Hallmarks of the underlying pathophysiology include a small left ventricular cavity due to concentric remodeling, impaired left ventricular compliance and left atrial dysfunction. This leads to an increase in left atrial and pulmonary pressure on exertion and in advanced stages of the disease already at rest with consecutive exertional dyspnea and exercise intolerance.

[Therapy of Heart Failure with Reduced Ejection Fraction: What's New in the 2021 Guidelines?].

Therapy of Heart Failure with Reduced Ejection Fraction: What's New in the 2021 Guidelines? The spectrum of treatment options for patients with heart failure with reduced ejection fraction (HFrEF) has substantially expanded over the last years. The 2021 guidelines of the European Society of Cardiology propose a new treatment algorithm for patients with HFrEF and define the role of the currently available drugs, interventions and devices in this context. The new standard is a basic therapy consisting of four drugs with different mechanisms of action for all patients with HFrEF: an angiotensin-converting enzyme inhibitor, a betablocker, a mineralocorticoid antagonist, and a sodium glucose co-transporter-2 inhibitor.

The "Spiked Helmet" Sign Associated with ST-Elevation Myocardial Infarction: A Case Report.

Introduction: The "spiked helmet" sign was first described in 2011 by Littmann and Monroe in a case series of eight patients. This sign is characterized by an ST-elevation atypically with the upward shift starting before the onset of the QRS complex. Nowadays the sign is associated with critical non-cardiac illness.